Tourmaline Bio, Inc.
TRML
$13.12
-$0.28-2.09%
| 12/31/2024 | 09/30/2024 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | -- | -- | |||
| SG&A Expenses | 3.00% | -18.10% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 5.60% | 11.23% | |||
| Operating Income | -5.60% | -11.23% | |||
| Income Before Tax | -10.20% | -15.38% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | -10.20% | -15.38% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -10.20% | -15.38% | |||
| EBIT | -5.60% | -11.23% | |||
| EBITDA | -5.60% | -11.23% | |||
| EPS Basic | -10.08% | -15.20% | |||
| Normalized Basic EPS | -48.10% | -15.18% | |||
| EPS Diluted | -10.08% | -15.20% | |||
| Normalized Diluted EPS | -48.10% | -15.18% | |||
| Average Basic Shares Outstanding | 0.11% | 0.17% | |||
| Average Diluted Shares Outstanding | 0.11% | 0.17% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||
